This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sonnet BioTherapeutics’s 8K filing here.
Sonnet BioTherapeutics Company Profile
Sonnet BioTherapeutics Holdings, Inc, a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues.
See Also
- Five stocks we like better than Sonnet BioTherapeutics
- Trading Halts Explained
- Semiconductor Giant Synopsys Slides 14% — Time to Take Notice
- Consumer Staples Stocks, Explained
- Tesla’s Closes in on $400: From Laggard to Leader in 2024
- Canadian Penny Stocks: Can They Make You Rich?
- Oracle’s Stock Price Rally Is Far From Over
